Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody

Author's Avatar
Jan 07, 2019
Article's Main Image

-- Initial data from the ongoing Phase 1 study in patients with B-cell malignancies expected in 2019 --

-- Xencor and Novartis to continue co-developing XmAb®14045, a CD123 x CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia --

PR Newswire